Pharmacokinetic study of darbepoetin alfa: Absorption, distribution, and excretion after a single intravenous and subcutaneous administration to rats

References

• Abels RI. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Seminars in Oncology 1992; 19(3 Suppl. 8)29–35
   PubMed Web of Science ®Google Scholar
• Allon M, Kleinman K, Walczyk M, Kaupke C, Messer-Mann L, Olson K, Heatherington AC, Maroni BJ. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clinical Pharmacology and Therapy 2002; 72: 546–555
   PubMed Web of Science ®Google Scholar
• Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrology and Dialysis Transplantation 2004; 19: 1224–1230
   PubMed Web of Science ®Google Scholar
• Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). British Journal of Cancer 2001; 84(Suppl. 1)3–10
   PubMed Web of Science ®Google Scholar
• Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoetin. Experimental Hematology 2003; 31: 290–299
   PubMed Web of Science ®Google Scholar
• Elliott SG, Lorenzini T, Strickland T, Delorme E, Egrie JC. Rational design of novel erythropoiesis stimulating protein (ARANESP): A super-sialated molecule with increased biological activity [abstract]. Blood 2000; 96: 82
   Web of Science ®Google Scholar
• Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. New England Journal of Medicine 1987; 316: 73–78
   PubMed Web of Science ®Google Scholar
• Eschbach JW, Haley NR, Adamson JW. The use of recombinant erythropoietin in the treatment of the anemia of chronic renal failure. Annals of the New York Academy of Sciences 1989b; 554: 225–230
   PubMedGoogle Scholar
• Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. New England Journal of Medicine 1989a; 321: 158–163
   PubMed Web of Science ®Google Scholar
• Ferrario E, Ferrari L, Bidoli P, De Candis D, Del Vecchio M, De Dosso S, Buzzoni R, Bajetta E. Treatment of cancer-related anemia with epoetin alfa: A review. Cancer Treatment Review 2004; 30: 563–575
   PubMed Web of Science ®Google Scholar
• Gavaret JM, Deme D, Nunez J, Salvatore G. Sequential reactivity of tyrosyl residues of thyroglobulin upon iodination catalyzed by thyroid peroxidase. Journal of Biology and Chemistry 1977; 252: 3281–3285
   PubMedGoogle Scholar
• Glaspy J, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Rigas J, Kuter D, Harmon D, Prow D, et al. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. British Journal of Cancer 2001; 84(Suppl. 1)17–23
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyian NS, Armstrong S, O’Byrne J, Rossi G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. British Journal of Cancer 2002; 87: 268–276
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Tchekmedyian NS. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology 2002; 16(10 Suppl. 11)23–29
   PubMedGoogle Scholar
• Henry DH. The evolving role of epoetin alfa in cancer therapy. Oncologist 2004; 9: 97–107
   PubMed Web of Science ®Google Scholar
• Herrington JD, Davidson SL, Tomita DK, Green L, Smith RE, Boccia RV. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. American Journal of Health System Pharmacology 2005; 62: 54–62
   PubMed Web of Science ®Google Scholar
• Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrology and Dialysis Transplantation 2003; 18: 362–369
   PubMed Web of Science ®Google Scholar
• MacDougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. Journal of the American Society of Nephrology 1999; 10: 2392–2395
   PubMed Web of Science ®Google Scholar
• Misaizu T, Shinkai H, Hirosawa T, Kaneko T. Metabolic fate of KRN5702: Plasma level, distribution, metabolism and excretion of KRN5702 after a single subcutaneous administration to rats. Xenobiotic Metabolism and Disposition 1993; 8: 73–91
   Google Scholar
• Nunez J, Pommier J. Formation of thyroid hormones. Vitamins and Hormones 1982; 39: 175–229
   PubMed Web of Science ®Google Scholar
• Patton J, Reeves T, Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist 2004; 9: 451–458
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G. A randomized comparison of every 2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004; 9: 696–707
   PubMed Web of Science ®Google Scholar
• Smith Jr RE, Jaiyesimi IA, Meza LA, Tchekmedyian NS, Chan D, Griffith H, Brosman S, Bukowski R, Murdock M, Rarick M, et al. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. British Journal of Cancer 2001; 84(Suppl. 1)24–30
   Google Scholar
• Uemura I, Niwa T, Nagao N, Misaizu T, Shinkai H. Metabolic fate of recombinant human erythropoietin (II)-plasma level, distribution, metabolism and excretion of 125I-KRN(5702) after single intravenous administration to rats. Clinical Report 1988; 22: 415–434
   Google Scholar